With $200 million in startup funding, a new Massachusetts-based drug company called EQRx is looking to shake up the pharmaceutical landscape, according to a Forbes report.
The company says it aims to develop ten new medicines over the next ten years, according to the report.
“We want to get great new medicines to people and society in a sustainable method,” EQRx CEO Alexis Borisy tells Forbes. “In a lot of ways, this is a very simple but perhaps very provocative idea.”
To read the full report, click here.